JOURNEE
-
octinoxate and
zinc oxide cream
Neocutis, Inc.
----------
JOURNEE
Drug Facts
Active ingredients
Octinoxate 7.5%
Zinc Oxide 7.3%
Purpose
Sunscreen
Uses
Warnings
For external use only
When using this product keep out of eyes. Rinse with water to remove.
Stop use and ask a doctor if rash or irritation develops and lasts.
Keep out of reach of children. In case of accidental ingestion, seek professional assistance or contact a Poison Control Center immediately.
Directions
Other information
Inactive ingredients
Water, Caprylic/ Capric Triglyceride, Hydrogenated c6-14 Olefin Polymers, Hexyldecanol, Glycerin, Glyceryl Stearate, PEG-100 Stearate, Potassium Cetyl Phosphate, Hydrogenated Palm Glycerides, Microcrystalline Cellulose, Camelia Sinensis Extract, Silica, Cutaneous Lysate, Sodium Ascorbyl Phosphate, Tocopheryl Acetate, Squalane, Hydroxyethyl Acrylate/Sodium Acryloyldimethyl Taurate Copolymer, Polyhydroxystearic Acid, Steareth-21, Melanin, Cetearyl Alcohol, Sodium Hyaluronate, Polysorbate 60, Triethoxycaprylsilane, Disodium EDTA, Xanthan Gum, Styrene/Acrylates Copolymer, Phenoxyethanol, Methylparaben, Ethylparaben, Propylparaben.
JOURNEE is the only day cream that combines PSP technology with antioxidants and broad spectrum UVA/UVB sun protection. Elegantly formulated JOURNEE revitalizes the skin while guarding against premature aging.
Years of research enabled the bioengineering of Processed Skin Proteins (PSP). PSP is a naturally balanced mixture of essential skin nutrients that nourish and revitalize the skin's outer layer. This clinically proven ingredient helps to beautifully rejuvenate the appearance of aged and stressed skin.
The light, non greasy formulation is fast absorbing and fragrance free. Green tea extract and melanin provide optimal Antioxidant protection.
JOURNEE is ideal for daily use and can be used on problematic or postprocedural skin.
All Skin Types.
www.NEOCUTIS.com
Questions? 866-636-2884
JOURNEE
NEO
SWISS TECHNOLOGY
NEOCUTIS
JOURNEE
octinoxate, zinc oxide cream |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Marketing Information | |||
Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
OTC monograph final | part352 | 03/31/2011 |
Labeler - Neocutis, Inc. (196482108) |
Establishment | |||
Name | Address | ID/FEI | Operations |
Englewood Lab, LLC | 172198223 | manufacture |